SCHEMBL1268492

SCHEMBL1268492

Cc1cc(NS(=O)(=O)c2ccc(C(F)(F)F)cc2Cl)ncc1Sc1ccc(S(=O)(=O)N2CCOCC2)cc1

nearest known ligand 0.45

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ GAA P10253 3/20 0.45
▸ PKM P14618 1/20 0.45
▸ EPHX2 P34913 2/20 0.41
▸ SCN9A Q15858 3/20 0.41
▸ PIK3C3 Q8NEB9 1/20 0.41
▸ LMNA P02545 6/20 0.41
▸ ALDH1A1 P00352 4/20 0.41
▸ SMN1; SMN2 Q16637 2/20 0.41
▸ HTT P42858 2/20 0.41
▸ POLB P06746 1/20 0.41
▸ GLA P06280 1/20 0.41
▸ L3MBTL1 Q9Y468 1/20 0.41
▸ MCOLN3 Q8TDD5 1/20 0.41
▸ TP53 P04637 1/20 0.39
▸ MCL1 Q07820 1/20 0.38
▸ CYP11B2 P19099 1/20 0.38
▸ MAPT P10636 1/20 0.38
▸ NPSR1 Q6W5P4 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1269747 0.92 ALDH1A1 (0.42) GAASCN9APIK3C3LMNAALDH1A1
SCHEMBL1268782 0.89 MAPK1 (0.43) GAALMNAALDH1A1SMN1; SMN2HTT
SCHEMBL12900168 0.88 GAA (0.48) GAAPKMEPHX2SCN9APIK3C3
SCHEMBL1269704 0.87 GAA (0.46) GAAPKMEPHX2SCN9APIK3C3
SCHEMBL1268674 0.86 GAA (0.42) GAAPKMEPHX2SCN9APIK3C3
SCHEMBL1269603 0.86 GAA (0.45) GAAPKMEPHX2SCN9APIK3C3
SCHEMBL1268685 0.84 GAA (0.43) GAAPKMEPHX2SCN9AHTT
SCHEMBL1268669 0.83 GAA (0.45) GAAPKMEPHX2SCN9ALMNA
SCHEMBL12931665 0.82 LMNA (0.45) GAAPKMEPHX2SCN9ALMNA
SCHEMBL1269489 0.81 GAA (0.43) GAAPKMEPHX2SCN9ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7893077-B2 Bisaryl-sulfonamides AMGEN INC. (US) 2011-02-22 — — US disclosed
EP-1786782-B1 BISARYL-SULFONAMIDES AMGEN INC (US) 2010-03-31 — — EP disclosed
US-20090221584-A1 Bisaryl-sulfonamides AMGEN INC. 2009-09-03 — — US disclosed
US-7544702-B2 Bisaryl-sulfonamides AMGEN INC. (US) 2009-06-09 — — US disclosed
EP-1786782-A2 BISARYL-SULFONAMIDES Amgen Inc. (US) 2007-05-23 — — EP disclosed
US-20060084802-A1 Bisaryl-sulfonamides AMGEN INC. 2006-04-20 — — US disclosed
WO-2006020830-A2 BISARYL-SULFONAMIDES AMGEN INC. (US) 2006-02-23 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090221584-A1 Bisaryl-sulfonamides PPARD, PPARA, PPARG GAA 1704/4885PKM 3049/4885EPHX2 1942/4885
US-20060084802-A1 Bisaryl-sulfonamides PPARD, PPARA, PPARG GAA 1704/4885PKM 3049/4885EPHX2 1942/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback